BEAMing and NSCLC

Monitoring resistance

Karlovich C, Goldman JW, Sun MS, et al. (2016) Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clin Cancer Res. 2016 Jan 8. [Epub ahead of print]
Pubmed

Piotrowska Z, Niederst MJ, Karlovich CA, et al. (2015) Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-positive cancers with a third generation EGFR inhibitor. Cancer Discov. 5(7):713-22.
Pubmed
Free PDF

Taus A, Hernandez A,  Del Carmen Vela M, et al. (2015) Monitoring treatment response in EGFR mutant non-small cell lung cancer patients using mutational load in circulating cell-free tumour DNA. J Clin Oncol 33, 2015 (suppl; abstr e19089)
Abstract

Thress K, Brant R, Carr TH, et al. (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 90(3):509-15.
Pubmed
Free PDF

Thress K, Yang J,  Ahn M, et al. (2014) Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor. Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349
Abstract
Poster

Our BEAMing Technology

Principle of Blood-based Testing

The value of ctDNA

Publications

The BEAMing technology

Method papers

The BEAMing technology

Concordance studies

BEAMing and mCRC

Publications

BEAMing and Breast cancer

Publications

BEAMing and Melanoma

Publications

Find your job at Sysmex Inostics
Check out our latest news
Contact Sysmex
Contact us!